When Francisco Leon talks about the medical science behind the biotech company he founded in 2023, it sounds like something out of a movie. The company, Tolerance Bio, focuses on preserving the body’s ...
Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...
Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...
INmune Bio (NASDAQ:INMB) announced on Monday a partnership with U.K.-based drug technology organization Cell and Gene Therapy Catapult to expand the manufacturing capabilities for its pipeline of cell ...
Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...
Jonathan Kotula: We think there needs to be a systems-level approach to deal with complex diseases such as cancer. A lot of what has been done so far are reductionist approaches—one small molecule for ...
Mo Khalil is the Hok Lam and Kathleen Kam Wong Professor of Bioengineering and Professor of Molecular and Cellular Biology at ...
Labroots and the Cell Biology Planning Committee are pleased to announce the 9th Annual Event in the Cell Biology Virtual Event Series 2025 on September 17th, 2025. This event provides an opportunity ...
Scientists at Duke-NUS Medical School have developed two powerful computational tools that could transform how researchers ...
Cells may generate their own electrical signals through microscopic membrane motions. Researchers show that active molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback